北京瑞强律师事务所 关于陕西盘龙药业集团股份有限公司 2025 年第二次临时股东会 之 法律意见书 二零二五年九月 0 地 址：北京市东城区银河 SOHO B 座 1509-1510 室 电 话：010-58116099 传 真：010-58116099 Email：Recher@bjrecher.com 北京瑞强律师事务所 2025 年第二次临时股东会 之 法律意见书 北京瑞强律师事务所（以下简称"本所"）接受陕西盘龙药业集团股份有限 公司（以下简称"公司"）的委托，指派本所陈晓昀律师、王志恒律师出席公司 于 2025 年 9 月 15 日下午 14:00 在陕西省西安市灞桥区现代纺织产业园灞柳二路 2801 号陕西盘龙医药股份有限公司二楼会议室召开的 2025 年第二次临时股东会 （以下简称"本次股东会"）。现依据《中华人民共和国公司法》（以下简称"《公 司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《深圳证券 交易所上市公司股东会网络投票实施细则》（以下简称"《网络投票细则》"） 《上市公司股东会规则》（以下简称"《股东会规则》"）等法律、行政法规、 其他规范性文件及《陕西盘龙药业集团股份 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 证券代码：002864 证券简称：盘龙药业 公告编号：2025-042 陕西盘龙药业集团股份有限公司 关于 2025 年第二次临时股东会决议公告 1.本次股东会未出现否决提案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议的情形。 一、会议召开和出席情况： （一）会议召开时间： 1.现场会议召开日期：2025 年 9 月 15 日（星期一）下午 14:00。 2.网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 9 月 15 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳 证券交易所互联网投票系统投票的具体时间为 2025 年 9 月 15 日 9:15—15:00 期间的任意时间。 （二）现场会议召开地点：西安市灞桥区现代纺织产业园灞柳二路2801号陕 西盘龙医药股份有限公司二楼会议室。 （三）会议召开和表决方式：采用现场表决与网络投票相结合的方式。 （四）召集人：陕西盘龙药业集团股份有限公司（以下简称"公司"）董事 会 ...

Core Insights - The company held a performance briefing for the first half of 2025, discussing key topics such as revenue growth, R&D progress, and future strategies [1][2][3] Revenue Performance - In the first half of 2025, the company's traditional Chinese medicine (TCM) decoction pieces saw a significant sales increase, achieving revenue of 123 million yuan, a year-on-year growth of 380.89%, and accounting for 21.42% of total revenue [1] - The company aims to continue expanding its TCM decoction business to enhance overall profitability [1] R&D Progress - The company reported R&D expenses of 15.85 million yuan in the first half of 2025, reflecting an 11.18% increase, outpacing the growth of over 72% in the TCM sector [2] - Multiple projects are advancing, including the TCM modified new drug PL-JT004 entering the CDE clinical acceptance stage and the chemical generic drug PL-JT001 completing BE testing [2] Digital Transformation - The company is embracing the "Internet + Medicine" trend, enhancing its digital marketing capabilities through a self-developed intelligent marketing platform, which has improved user lifecycle management efficiency by 40% and marketing response speed by 60% [3] - The company has established a professional digital marketing team and deepened strategic cooperation with major e-commerce platforms [3] Investor Engagement - The company has conducted nine investor research activities this year, indicating strong investor interest and recognition in the capital market, with the fastest revenue growth among TCM companies that have held at least nine research activities [3][4]

Core Viewpoint - The company held an online roadshow on September 10, 2025, to engage with investors regarding its traditional Chinese medicine (TCM) formula granules, innovative drug research and development, and various business segments [1] Business Growth and Strategic Layout - The company completed the construction of an intelligent production line for TCM formula granules by the end of 2024, establishing a business development center and a professional team, with 310 varieties developed and registered for market in 18 provinces, indicating the business is in its early stages and expanding from Shaanxi province [1] Innovative Drug Research and Development - In the first half of 2025, the company accelerated its innovative drug research, with the modified TCM new drug PL-JT004 entering the CDE clinical acceptance stage, and chemical generic drugs PL-JT001 completing BE testing and awaiting production reporting [2] - The company aims to cultivate major products through a gradient pipeline layout, with various innovative drugs progressing through preclinical and Phase II work [2] Business Segment Development - Revenue from TCM decoction pieces increased by 380.89% year-on-year in the first half of 2025, with its revenue share rising from 5.62% to 21.42%, although the gross margin fell by 8.46% to 3.49% [2] - The health products and daily chemicals segment saw a revenue increase of 47.49%, but its revenue share remains low at 0.14%, indicating rapid growth but small scale [2] - The chemical drug layout focuses on the fields of "rheumatism and bone diseases, chronic pain," targeting generic drugs with proven efficacy, expired patents, and significant market potential [2] Market Expansion and Management - The company employs a "professional academic promotion model" for grassroots markets, covering over 5,000 medical institutions, 30,000 retail pharmacies, and 20,000 grassroots medical units [3] - The company is enhancing its digital marketing capabilities through a self-developed intelligent marketing platform and partnerships with major e-commerce platforms [3] - Operating cash flow decreased by 43.66% year-on-year due to increased inventory procurement, while accounts receivable grew due to the low gross margin of TCM decoction pieces [3] - The company is addressing the risk of rising raw material prices by forming a procurement team and leveraging local TCM resources to establish a full industry chain [3]

Group 1: Financial Performance - The company achieved a revenue of 574.02 million yuan in the first half of 2025, representing a year-on-year increase of 118.44 million yuan, with a growth rate of 26.06% [14] - The net profit attributable to the parent company was 60.14 million yuan, showing a slight increase of 0.48 million yuan, with a growth rate of 0.81% [14] - The operating cash flow net amount decreased by 43.66% year-on-year, primarily due to increased inventory procurement payments [17] Group 2: Business Development and Strategy - The company has established a Traditional Chinese Medicine (TCM) formula granule business development center, completing the research and registration of 310 products, with approvals in 18 provinces [11] - The company is focusing on the "one body, two wings, three depths" strategy to expand its market share while enhancing profitability [3][6] - The company is actively pursuing the "Internet + medicine" strategy, enhancing digital marketing capabilities and collaborating with major e-commerce platforms [18][10] Group 3: Product and Market Insights - The revenue from TCM decoction pieces increased by 380.89% year-on-year, but the gross profit margin was only 3.49%, down 8.46% [5] - The company is addressing the low gross profit margin in the TCM decoction segment by expanding sales scale and reducing procurement costs [5][12] - The company is developing a diverse product ecosystem, including oral and external preparations, to strengthen its core competitiveness [15] Group 4: Investor Relations and Shareholder Value - The company maintains a dividend payout ratio of 17.6%, with plans to balance shareholder returns with long-term growth [4] - The company is committed to enhancing investor confidence through regular communication and transparent information disclosure [7] - The company is exploring share buybacks and other measures to stabilize market value [7] Group 5: Regulatory and Market Challenges - The company is adapting to stricter regulations in the TCM industry by enhancing compliance and quality management throughout the production process [13] - The impact of national medical insurance cost control and centralized procurement policies is being closely monitored, with strategies in place to mitigate potential effects [24] - The company is addressing the risks associated with rising prices of core raw materials by maintaining sufficient cash reserves and strategic procurement [21]

Group 1 - The company announced a cash dividend distribution plan for the first half of 2025, proposing a distribution of 1.00 yuan (including tax) for every 10 shares held by shareholders [2] - The total share capital used for the dividend calculation is 105,907,460 shares, after excluding 373,500 shares held in the repurchase account [2] - The record date for the dividend is set for September 15, 2025, and the ex-dividend date is September 16, 2025 [2]

证券代码：002864 证券简称：盘龙药业 公告编号：2025-040 陕西盘龙药业集团股份有限公司 关于召开 2025 年第二次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司于 2025 年 8 月 28 日在巨潮资讯网上披露了《关于 召开 2025 年第二次临时股东会的通知》（公告编号：2025-035），现发布本次股东会 的提示性公告如下： 一、召开会议的基本情况 1.股东会届次：2025 年第二次临时股东会； 6.会议的股权登记日：2025 年 9 月 5 日； 7.出席对象： 1 （1）在股权登记日持有公司股份的普通股股东或其代理人； 2.股东会的召集人：陕西盘龙药业集团股份有限公司（以下简称"公司"）董事会； 3.会议召开的合法、合规性：经公司第四届董事会第二十五次会议审议通过，决定 召开公司 2025 年第二次临时股东会，本次会议的召开符合《中华人民共和国公司法》 《上市公司股东会规则》《深圳证券交易所股票上市规则》等有关法律法规及《公司章 程》的规定。 4.会议召开的日期、时间： （1）现场 ...

证券代码：002864 证券简称：盘龙药业 公告编号：2025-039 陕西盘龙药业集团股份有限公司 2025 年半年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本次除权除息前公司总股本为 106,280,960 股，按总股本折算的每 10 股现金 分红(含税)=( 现金分红总额/总股本)*10=(10,590,746.00 元/106,280,960 股)*10=0.996485 元(保留到小数点后六位，最后一位直接截取，不四舍五入)。 特别提示： 1.陕西盘龙药业集团股份有限公司（以下简称"公司"）回购专用账户持有 的股份 373,500 股不参与本次权益分派。 2.公司 2025 年半年度权益分派方案为：以公司现有总股本 106,280,960 股剔 除回购专用账户中已回购股份 373,500 股后的股本 105,907,460 股为基数，向全 体股东每 10 股派发现金分红 1.00 元（含税）。公司本次实际派发的现金分红总 额 = 实 际 参 与 分 配 的 总 股 本 * 分 配 比 例 ， 即 105,907,460 股 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002864 证券简称：盘龙药业 公告编号：2025-038 一、业绩发布会的安排 1、召开时间：2025年9月10日（星期三）下午15:00-17:00 2、召开方式：同花顺路演平台采用网络远程平台文字互动方式 3、出席人员：董事长谢晓林先生，董事会秘书吴杰先生，独立董事任海云女士，独立董事牛晓峰先 生，副总裁、研究院院长张德柱先生，财务总监祝凤鸣先生。 二、投资者参与方式 问题征集方式：https://board.10jqka.com.cn/fe/roadshow/questionCollection.html?id=1010629 陕西盘龙药业集团股份有限公司 关于举行2025年半年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假 记载、误导性陈述或重大 遗漏。 陕西盘龙药业集团股份有限公司（以下简称"公司"）于2025年8月28日在巨潮资讯网 （www.cninfo.com.cn）上披露了《2025 年半年度报告》。为使广大投资者更加全面、深入地了解公司 经营情况，公司将于2025年9月10日召开2 ...

Group 1 - The company, Panlong Pharmaceutical, announced that it will hold an online performance briefing for the first half of 2025 on September 10, 2025, from 15:00 to 17:00 [2]